

CLAIMS

1 1. 10-Propargyl-10-deazaaminopterin, substantially free of 10-
2 deazaaminopterin.

1 2. A composition consisting essentially of 10-Propargyl-10-
2 deazaaminopterin.

1 3. A pharmaceutical composition comprising 10-Propargyl-10-
2 deazaaminopterin, substantially free of 10-deazaaminopterin, and a pharmaceutically
3 acceptable carrier.

1 4. A method for treatment of tumors comprising administering to
2 a human patient diagnosed as having a tumor a therapeutically effective amount of 10-
3 propargyl-10-deazaaminopterin, substantially free of 10-deazaaminopterin.

1 5. The method according to claim 4, wherein the tumor is a solid
2 tumor.

1 6. The method according to claim 4, wherein the 10-propargyl-10-
2 deazaaminopterin, substantially free of 10-deazaaminopterin, is administered in
3 amounts of from 40 to 120 mg/m² of body surface area/day.

1 7. The method according to claim 5, wherein the tumor is a
2 mammary tumor.

1 8. The method according to claim 4, wherein the tumor is a lung
2 tumor.